Aquestive Therapeutics, Inc.
AQST· Nasdaq
AQSTAquestive Therapeutics, Inc.
Filed Mar 8, 2022 · 10-K · 67 days after period end · 0001628280-22-005393
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $11.08M | $7.15M | $16.42M | $16.82M |
| Net Income | -$28.95M | -$20.37M | -$12.64M | -$13.94M |
| EPS Diluted | — | -$0.60 | -$0.48 | -$0.56 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aquestive Therapeutics, Inc. · CIK 1398733 · Engraved from SEC EDGAR
ended Dec 31, 2021 · filed Mar 8, 2022 · 67 d after period end
